Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 15 to 23 amino acid residues in defined sequence
Reexamination Certificate
1999-07-02
2002-10-29
Russel, Jeffrey E. (Department: 1653)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
15 to 23 amino acid residues in defined sequence
C514S002600, C514S013800, C514S014800, C514S015800, C514S016700, C530S327000, C530S328000, C530S329000, C530S345000
Reexamination Certificate
active
06472507
ABSTRACT:
BACKGROUND
The pharmaceutical industry has for many years concerned itself with the efficient delivery of therapeutic agents. This problem may be attributed to the short clearance time of the agent in the body (short half-life), the location of the site of action or possibly the nature of the therapeutic agent itself, for example, its solubility, hydrophobicity etc. Thus, many developments and strategies have been adopted, including formulating the therapeutic agent so as to protect it from a hostile environment on route to its site of action, by for example, enterically coated tablets, controlled release devices and the like.
The development of peptide derived therapeutic agents has posed a further problem due their susceptibility to enzymatic degradation not only in the GI tract but also in the bloodstream. An example of how this problem has been addressed relates to the incorporation of the peptides into liposomes or polymeric microspheres that target the peptides to the lymph system.
A further related problem, especially for therapeutic agents that function intracellularly is the barrier posed by the cell membrane. Thus, it may be possible to increase the half life of the agent or ensure that it passes through the body without being degraded, but many agents must actually enter cells to exert their therapeutic effect.
European Patent 485578 discloses that the homeodomain and specifically, helix 3 of a homeobox peptide, particularly that derived from the Drosophila Antennapedia, is of use as an intracellular transport vector. The patent disclosed that a specific 57 amino acid sequence of a Drosophila Antennapedia homeopeptide (referred to as the pAntp peptide) was capable of penetrating fibroblasts and embryo cells (in vivo). Emphasis was placed upon the last 27 amino acids of the sequence that correspond with the helix 3 and 4. There is no description of the pAntp peptide being linked to any other peptide or therapeutic agent.
Subsequent disclosures (Derossi D et al., J Biol Chem (1994) 269, 10444-10450, Joliot A H et al., (1991) The New Biol 3, 1121-1134 and PNAS (1991) 88, 1864-1868, Perez F et al., J Cell Sci (1992) 102, 712-722), all disclose how a 16 amino acid synthetic peptide derived from the third helix of the Antennapedia homeodomain may be used for the intracellular delivery of bioactive products and antisense oligonucleotides. The amino acid sequence of use is RQIKIWFQNRRMKWKK (SEQ ID No. 1) also known as Penetratin®.
In an effort to prevent the enzymatic cleavage of this peptide Brugidou J et al., (Biochem Biophys Res Comm (1995) 214(2), 685-693) prepared a retro-inverso form (D amino acids in reverse order) of SEQ ID No. 1, substituting the two isoleucine resides at positions 3 and 5 of penetratin with valine and adding a glycine residue at the C-terminus to facilitate binding to a resin. A further retro-inverso form was prepared replacing the extra glycine with a cholesterol moiety attached via a sulfhydryl linker group. The addition of the cholesterol moiety improved penetration due to the increased hydrophobicity of the molecule.
This development of the retro-inverso form of penetratin has given rise to WO 97/12912 that discloses peptides of 16 amino acids comprising between 6 and 10 hydrophobic amino acids wherein the sixth amino acid from either end is tryptophan. This disclosure attempts to define the minimal characteristics of sequences capable of acting as internalisation vectors.
Penetratin, its analogues and retro-inverso forms have therefore been described as being of use as a carrier to facilitate the cellular internalisation of conjugated peptides or oligonucleotides.
SUMMARY OF THE INVENTION
The present invention aims to provide a delivery system for therapeutic drugs that is capable of facilitating the internalisation of the drug into cells, thus enhancing the delivery and/or therapeutic effect of the drug. The delivery system may also improve the half-life of the drug in the human or animal body, improve its solubility in biological fluids, minimise known toxic or non-desirable side-effects, enhance the onset of action of the desired therapeutic effect, provide alternative routes for the adminstration of the drug, enhance the biodistribution and metabolism of the drug moiety and decrease the incidence of drug resistance.
The present invention relates to a novel drug delivery system of use in the improved delivery of drug therapeutic agents into target cells. The delivery system provides other benefits that include enhancement in terms of the metabolism, distribution and excretion of the drug. The delivery system may be therapeutically active in both its intact and dissociated states.
Thus, the invention relates to a delivery system comprising a drug moiety linked to a carrier moiety comprising a homeobox peptide or fragment or derivative thereof. As is discussed hereinafter, the drug moiety is not a peptide or oligonucleotide and the carrier moiety may be a derivative of penetratin.
REFERENCES:
patent: 4847240 (1989-07-01), Ryser et al.
patent: 5043329 (1991-08-01), Lichtenberger
patent: 5179086 (1993-01-01), Flender
patent: 5580563 (1996-12-01), Tam
patent: 5888762 (1999-03-01), Joliot et al.
patent: 6025140 (2000-02-01), Langel et al.
patent: 6080724 (2000-06-01), Chassaing et al.
patent: WO 91/18981 (1991-12-01), None
patent: WO 97/12912 (1997-04-01), None
patent: WO 97/19954 (1997-06-01), None
patent: WO 98/13059 (1998-04-01), None
patent: WO 99/05302 (1999-02-01), None
patent: WO 99/11809 (1999-03-01), None
Brugidou, J. et al. (1995) “The Retro-Inverso Form of a Homobox-Derived Short Peptide Is Rapidly Internalised by Cultured Neurones: A New Basis For An Efficient Intracellular Delivery System” Biochemical and Biophysical Research Communications, vol. 214, No. 2, pp. 685-693.
Derossi, Daniele et al. (1998) “Trojan Peptides: The Penetratin System For Intracellular Delivery” Trends In Cell Biology, vol. 8, pp. 84-87.
Prochiantz, Alain (1996) “Getting Hydrophilic Compounds Into Cells: Lessons From Homeopeptides” Current Opinion in Neurobiology, vol. 6, pp. 629-634.
Fischer Peter M.
Wang Shudong
Zhelev Nikolai
Cyclacel Limited
DiConti, Jr. Giulio A.
Kanik Cynthia L.
Lahive & Cockfield LLP
Russel Jeffrey E.
LandOfFree
Carrier based drug delivery system does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Carrier based drug delivery system, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carrier based drug delivery system will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2922577